To establish the clinical relevance of our results, we investigated the immune response gene expression in BRCA2-deficient ovarian serous cystadenocarcinomas using mRNA expression data available in The Cancer Genome Atlas (TCGA; Fig. 5). The gene discussed is BRCA2; the disease is ovarian serous cystadenocarcinoma.